1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Gerresheimer AG

Gerresheimer AG

GXI.DE
Gerresheimer AGDE flagDeutsche Börse
28.48
EUR
-0.60
- -
983.70MMarket Cap
Gerresheimer AG
GXI.DE
(Deutsche Börse)

Recent

price

28.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
32.64
34.86
38.82
40.32
41.08
40.86
43.8
42.94
43.56
44.34
45.18
47.71
57.87
59.71
57.65
67.19
63.35
Revenue per Share
1.49
1.61
1.98
1.98
2.11
3.32
3.87
3.21
4.11
2.57
2.82
2.67
3.06
3.48
2.38
-9.27
1.83
Basic EPS, GAAP
2.76
1.39
1.74
0.88
1.04
2.48
2
3.27
1.88
6.14
1.56
0.27
7.07
8.83
6.92
6.07
6.93
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.25
Dividend per Share
-1.22
-0.61
-0.35
0.79
1.96
4.6
7.61
9.88
13.57
14.61
16.09
18.16
20.57
21.29
21.64
27.26
22.67
Book Value per Share
1.34
0.3
0.27
-0.29
1.49
-17.62
-13.71
-9.93
-19.6
-13.24
-11.93
-8.73
-1.53
6.11
7.78
-10.64
-7.97
Tangible Book Value per Share
31
31
31
31
31
31
31
31
31
31
31
31
31
33
35
35
35
Basic Weighted Avg Shares
1,025
1,095
1,219
1,266
1,290
1,283
1,375
1,348
1,368
1,392
1,419
1,498
1,817
1,990
1,991
2,321
2,188
Sales/Revenue/Turnover
9.27
10.03
11.45
11.07
11.32
10.33
13.33
13.38
14.05
2.39
12.75
12.64
10.66
11.53
9.65
-3.05
9.68
Operating Margin (%)
106
101
84
83
104
109
126
125
137
270
146
145
172
186
204
522
237
Depreciation Expense
47
51
62
62
66
104
122
101
129
81
89
84
96
116
82
-320
63
Net Income, GAAP
22.99
24.94
30.65
30.65
26.67
29.41
28.89
29.17
- -
15.78
33.49
31.77
27.43
28.28
23.59
- -
23.32
Effective Tax Rate (%)
4.56
4.61
5.09
4.91
5.14
8.12
8.84
7.48
9.43
5.8
6.24
5.59
5.29
5.83
4.13
-13.8
2.89
Profit Margin (%)
28
145
120
53
46
-130
2
42
-196
-346
-27
-229
-291
-117
-33
-258
8
Working Capital
- -
442
408
389
371
727
730
681
674
497
837
695
685
658
916
1,599
1,702
LT Debt
529
537
538
563
604
698
763
790
890
942
900
1,015
1,269
1,467
1,505
1,107
1,466
Total Equity
14.21
10.32
9.46
9.43
9.77
6.57
7.61
7.29
- -
1.46
6.1
6.27
6.01
6.51
5.49
- -
5.16
Return on Invested Capital (%)
-368.8
28.7
16.32
15.79
14.48
13.36
8.4
9.79
- -
6.87
6.59
5.74
6.1
8.07
6.59
- -
5.58
Return on Capital (%)
- -
- -
- -
- -
153.56
101.15
63.46
36.75
35.03
18.26
18.37
15.58
15.81
17.13
11.29
-37.93
8.37
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'24
Nov'24
May'25
ST Debt
605
366
505
LT Borrowings
- -
871
- -
LT Finance Leases
- -
45
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
3,575
2,580
2,188

Working Capital

FRC

•

in mil. unless spec.
Aug'24
Nov'24
May'25
Total Current Assets
877
960
1,138
Cash, Cash Equivalents & STI
131
213
203
Accounts Receivable, Net
273
272
291
Inventories
372
356
505
Total Current Liabilities
1,089
993
1,130
Payables & Accruals
- -
- -
- -
ST Debt
605
366
505
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.64%
5.92%
-26.43%
Free Cash Flow
259.96%
489.04%
-12.31%
Net Income, GAAP
-48.86%
-97.67%
-489.32%
Sales/Revenue/Turnover
6.34%
10.6%
16.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
458
500
488
545
1,990
2024
466
502
499
569
1,991
2025
520
601
639
- -
2,321

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.38
1.05
0.81
- -
3.48
2024
0.38
0.94
0.79
- -
2.38
2025
-0.52
0.49
- -
- -
-9.27

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
1.25
- -
- -
2024
- -
- -
1.25
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Becton, Dickinson and Company (BDXA)
Supermax Corporation Berhad (SPMXF)
Baxter International Inc. (BAX)
InfuSystem Holdings, Inc. (INFU)
Sector 10, Inc. (SECI)
Merit Medical Systems, Inc. (MMSI)
Business
Gerresheimer AG, along with its associated companies, develops, produces, and globally supplies specialized primary packaging and innovative drug administration systems. The company operates through its Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices segment delivers sophisticated drug delivery systems, encompassing solutions like inhalers, insulin pens, auto-injectors, and prefillable plastic syringes for the pharmaceutical, biotech, diagnostics, and medical technology sectors. Additionally, it provides diverse containers and closures for solid, liquid, and ophthalmic applications, including PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and various accessories, alongside prescription vials. This division also engages in contract manufacturing for complex medical devices. The Primary Packaging Glass division manufactures high-quality glass primary packaging for both the pharmaceutical and cosmetics industries. Its offerings include infusion, dropper, and syrup bottles, alongside injection vials, ampoules, and cartridges, often available in different glass types and colors such as clear, amber, or opal. The division further extends to miniature bottles and glass containers for liquid food, spices, and spirits, as well as specialized packaging for fragrances, deodorants, skincare, and wellness products. Recent innovations include Gx Elite vials, enhancing patient safety and manufacturing efficiency for sensitive drugs. The Advanced Technologies division is dedicated to pioneering smart drug delivery systems. This includes the development of micro pumps, digital platforms for therapeutic support, and wearable medication pumps designed for self-administration of critical medicines, catering to pharmaceutical and biotech partners. Recent advancements in this area include expanded collaboration on reusable autoinjector platforms and partnerships in connected adherence solutions. Founded in 1864, the company is headquartered in Düsseldorf, Germany. Gerresheimer maintains a global presence with over 40 production sites across Europe, the Americas, and Asia. The company is strategically focused on high-value solutions and sustainable growth, as evidenced by its validated CO2e reduction targets.